ARTICLE | Emerging Company Profile
Tallac: linking antibodies to DNA-triggered innate immunity
Emerging Company Profile: Tallac launches with $62M A round, pipeline of antibody-TLR9 agonist conjugates
December 9, 2020 1:24 AM UTC
Tallac debuted last week with a $62 million series A round to advance a pipeline of systemically delivered antibody conjugates designed to trigger innate immunity against cancer.
The tranched round included venBio Partners, Morningside Venture, Lightstone Ventures, Matrix Partners China and MRL Ventures Fund...
BCIQ Target Profiles